CATEGORIES: Research | TRIAD

Using Zebrafish to Search for Therapeutics for CMT2A

by | May 16, 2014 | 1 comment

Zebra 4Research on CMT is global, and covers both laboratory and clinical studies. It is critically important to be aware of what is happening elsewhere as well as in the USA because it can have implications for what we do and fund at the HNF. In June of 2014, a paper was published in PLOS ONE by Chapman et al. (from the laboratory of Dr. Andrew Grierson at the University of Sheffield, UK) that caught our attention.

While we frequently see researchers using mice and rats as animal models of diseases, sometimes they are unsuitable for knocking out genes due to embryonic lethality. Many researchers have turned to the humble zebrafish to further their understanding of genetic disorders, and this investigation was no exception. By using the zebrafish as a model of CMT2A, (which a ffects the distal axons of motor and sensory neurons in humans), the study was able to examine how the mitofusin 2 (MFN2) affects the phenotype in the zebrafish.

Using zebrafish in genetic research is an active field, but there have been some limitations on the availability of genetic models of diseases. Genome editing technology, however, has developed rapidly, so it is now quick and cheap to make mutations in almost every gene now. Screens in fish are longstanding for studies of development. The MFN2 fish doesn’t get a phenotype until it is older, so it can be a much harder task.

Almost all human disease genes have an equivalent in zebrafish. Zebrafish are Vertebrates (as they have a spinal cord), which is critical for modeling disorders of the motor system such as CMT. Zebrafish are highly fertile and it is possible to generate hundreds of fish bearing the CMT2A mutation in a short time. Testing can then be done to measure the effect of various therapies and see which ones show the most promise for future use in human CMT patients.

As the mitochondria are the energy source of the cell, any gene mutations that affect their function can have far reaching implications for health and can cause CMT2A as well as other neurodegenerative diseases like Parkinson’s disease.The zebrafish are frequently used as a model of human diseases of the nervous system such as ALS and spinal muscular atrophy. While zebrafish created with this mutation in MFN2 initially developed normally, they showedprogressive motor dysfunction between 100 and 200 days old. Some patients with mutation of the MFN2 gene also show progressive motor dysfunction. In the study, fish were monitored by video in their aquarium and those that swam at an angle of more than 30 degrees to the horizontal were recorded. In vitro cell culture was used to measure mitochondria transport in the neurons from the MFN2 knock out zebrafish and retrograde transport was decreased.

While humans and zebrafish certainly do not look alike, their mitofusin 2 proteins are very similar. This study presented a very useful animal model of CMT2A that can be explored further to test potential drugs.

We hope to report on future developments from this laboratory as the HNF is contracted to support targeted therapeutic experiments for one year.

Learn more on this topic

Related Blog Posts

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Hot off the press

Some recent papers on Charcot-Marie-Tooth (CMT) disease go to show that we are steadily and impressively peeling back the complexity of the biology even though it is a relatively common rare disease with several thousand publications on it.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

1 Comment

  1. Tabitha

    Awesome let me know if they do seeing I have CMT2A lol

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news